Investors are ditching this gene therapy stock en masse, for good reason.
News & Analysis: Bluebird Bio
The company had to halt one of its clinical studies following a suspected severe adverse reaction.
The biotech will then focus on its rare disease programs.
The hematology space is hot.
Targeting BCMA is all the rage, but who will come out on top?
The battle for beta thalassemia and sickle cell disease patients is heating up.
Naughty or nice, shareholders aren't getting anything on their wish lists from these stocks this year.
Another manufacturing issue set the biotech's sickle cell disease program back much further than investors had hoped.
A delay in submitting its sickle cell treatment to the FDA will push back a major source of future revenue.
The road ahead may be a bit rocky, but investing in these companies may pay off big-time -- eventually.